esc-derived basal forebrain cholinergic neurons ameliorate the cognitive symptoms associated with alzheimer’s disease in mouse models
Clicks: 155
ID: 146737
2015
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Popular Article
30.0
/100
154 views
9 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Degeneration of basal forebrain cholinergic neurons (BFCNs) is associated with cognitive impairments of Alzheimer’s disease (AD), implying that BFCNs hold potentials in exploring stem cell-based replacement therapy for AD. However, studies on derivation of BFCNs from embryonic stem cells (ESCs) are limited, and the application of ESC-derived BFCNs remains to be determined. Here, we report on differentiation approaches for directing both mouse and human ESCs into mature BFCNs. These ESC-derived BFCNs exhibit features similar to those of their in vivo counterparts and acquire appropriate functional properties. After transplantation into the basal forebrain of AD model mice, ESC-derived BFCN progenitors predominantly differentiate into mature cholinergic neurons that functionally integrate into the endogenous basal forebrain cholinergic projection system. The AD mice grafted with mouse or human BFCNs exhibit improvements in learning and memory performances. Our findings suggest a promising perspective of ESC-derived BFCNs in the development of stem cell-based therapies for treatment of AD.
| Reference Key |
yue2015stemesc-derived
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Wei Yue;Yuanyuan Li;Ting Zhang;Man Jiang;Yun Qian;Min Zhang;Nengyin Sheng;Su Feng;Ke Tang;Xiang Yu;Yousheng Shu;Chunmei Yue;Naihe Jing |
| Journal | nature reviews gastroenterology & hepatology |
| Year | 2015 |
| DOI |
10.1016/j.stemcr.2015.09.010
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.